Treatment for obstructive sleep apnoea and cardiovascular diseases: are we aiming at the wrong target?

Raphael Heinzer, Danny Eckert

    Research output: Contribution to journalComment/debate

    1 Citation (Scopus)

    Abstract

    Despite a robust design and good statistical power, the ISAACC study1 (Impact of Sleep Apnea syndrome in the evolution of Acute Coronary syndrome. Effect of intervention with CPAP), similar to the SAVE study (Sleep Apnea cardioVascular Endpoints),2 did not show a positive effect of obstructive sleep apnoea (OSA) treatment with continuous positive airway pressure (CPAP) as a secondary prevention for cardiovascular events. The modest but clinically similar use of CPAP (<3 h per night) observed in this study and in SAVE might explain, at least in part, this absence of an effect. However, when the authors compared participants with acute coronary syndrome (ACS) without OSA (reference group) with participants with ASC and OSA who were given usual care (usual care group, no CPAP), they did not find any significant differenceon the recurrence of cardiovascular events. This intriguing finding raises further questions regarding the effect of OSA on cardiovascular events.
    Original languageEnglish
    Pages (from-to)323-325
    Number of pages3
    JournalThe Lancet Respiratory Medicine
    Volume8
    Issue number4
    DOIs
    Publication statusPublished - Apr 2020

    Keywords

    • sleep apnoea
    • obstructive sleep apnoea (OSA)
    • cardiovascular diseases
    • acute coronary syndrome (ACS)
    • recurrence of cardiovascular events
    • continuous positive airway pressure (CPAP)

    Fingerprint Dive into the research topics of 'Treatment for obstructive sleep apnoea and cardiovascular diseases: are we aiming at the wrong target?'. Together they form a unique fingerprint.

  • Cite this